An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial. X. Long Zheng, MD, PhD: Now we can talk about caplacizumab.
X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment. X. Long Zheng, MD, PhD: What are the unmet needs in acquired TTP [thrombotic thrombocytopenic purpura] ...
Time to progression (TTP) is suggested as a reliable endpoint compared with the progression-free survival in the clinical trials of hepatocellular carcinoma (HCC). However, the correlation between TTP ...
The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.
Patients with acquired thrombotic thrombocytopenic purpura experienced a faster normalization of platelet count when treated with caplacizumab than placebo, according to results of a randomized phase ...
License obtained from Kaketsuken is worldwide and exclusive except for Japan. Baxter International received a worldwide license to Kaketsuken’s drug candidate for the treatment of thrombotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback